bims-instec Biomed News
on Intestinal stem cells and chemoresistance in colon cancer and intestinal regeneration
Issue of 2025–06–29
twelve papers selected by
Maria-Virginia Giolito, Université Catholique de Louvain



  1. Int Immunopharmacol. 2025 Jun 20. pii: S1567-5769(25)01105-1. [Epub ahead of print]162 115115
      Colorectal cancer (CRC) liver metastasis involves complex interactions between tumor cells and the microenvironment, but the mechanisms remain unclear. This study identified macrophage-derived l-glutamine as a key metabolite driving communication between macrophages and CRC cells in liver metastases. Macrophages produced l-glutamine, which CRC cells sensed through the metabolic regulatory role of SLC3A2. This sensing process influenced the activation of genes linked to cell adhesion, including enhancer-driven genes regulated by the transcription factor FOXA2. Knocked down SLC3A2 in metastatic CRC cells reduced FOXA2 expression, impairing cell proliferation and adhesion to hepatocytes. Overexpressed FOXA2 in these cells partially restored their proliferation and adhesion abilities. These findings highlight that macrophage-derived l-glutamine promoted CRC cell proliferation and adhesion by regulating FOXA2 activity through SLC3A2-mediated metabolic sensing. This study has uncovered a novel mechanism of metabolite-mediated communication and epigenetic regulation in CRC liver metastases, providing potential therapeutic targets.
    Keywords:  Colorectal Cancer; FOXA2; Liver metastasis; Macrophages; SLC3A2; l-glutamine
    DOI:  https://doi.org/10.1016/j.intimp.2025.115115
  2. J Cell Biol. 2025 Aug 04. pii: e202409103. [Epub ahead of print]224(8):
      Hypoxia-inducible factors (HIFs) mediate cellular responses to low oxygen, notably enhanced fermentation that acidifies poorly perfused tissues and may eventually become more damaging than adaptive. How pH feeds back on hypoxic signaling is unclear but critical to investigate because acidosis and hypoxia are mechanistically coupled in diffusion-limited settings, such as tumors. Here, we examined the pH sensitivity of hypoxic signaling in colorectal cancer cells that can survive acidosis. HIF-1α stabilization under acidotic hypoxia was transient, declining over 48 h. Proteomic analyses identified responses that followed HIF-1α, including canonical HIF targets (e.g., CA9, PDK1), but these did not reflect a proteome-wide downregulation. Enrichment analyses suggested a role for lysosomal degradation. Indeed, HIF-1α destabilization was blocked by inactivating lysosomes, but not proteasome inhibitors. Acidotic hypoxia stimulated lysosomal activity and autophagy via mammalian target of rapamycin complex I (mTORC1), resulting in HIF-1α degradation. This response protects cells from excessive acidification by unchecked fermentation. Thus, alkaline conditions are permissive for at least some aspects of HIF-1α signaling.
    DOI:  https://doi.org/10.1083/jcb.202409103
  3. Nat Metab. 2025 Jun 26.
      Increased reactive oxygen species (ROS) levels are a hallmark of inflammatory bowel disease (IBD) and constitute a major mechanism of epithelial cell death. Approaches to broadly inhibit ROS have had limited efficacy in treating IBD. Here we show that lipid peroxidation contributes to the pathophysiology of IBD by promoting ferroptosis, an iron-dependent form of programmed cell death. Mechanistically, we provide evidence of heterocellular crosstalk between intestinal fibroblasts and epithelial cells. In IBD tissues and mouse models of chronic colitis, acyl-CoA synthetase long-chain family 4 (ACSL4) is overexpressed in fibroblasts. ACSL4 in fibroblasts reprograms lipid metabolism and mediates intestinal epithelial cell sensitivity to ferroptosis. In mouse models, overexpressing ACSL4 in fibroblasts results in increased intestinal epithelial ferroptosis and worsened colitis, while pharmacological inhibition or deletion of fibroblast ACSL4 ameliorates colitis. Our work provides a targeted approach to therapeutic antioxidant treatments for IBD.
    DOI:  https://doi.org/10.1038/s42255-025-01313-x
  4. Cell Rep Med. 2025 Jun 20. pii: S2666-3791(25)00274-5. [Epub ahead of print] 102201
      The treatment of patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) remains a significant clinical challenge. Cetuximab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb), induces immunogenic cell death, potentially synergizing with immune checkpoint inhibitors. The phase 2, proof-of-concept, single-arm AVETUXIRI trial (ClinicalTrials.gov: NCT03608046) evaluates the safety and efficacy of cetuximab, irinotecan (a topoisomerase I inhibitor), and avelumab (an anti-programmed cell death ligand 1 [PD-L1]) in 57 patients with RAS wild-type or mutated MSS mCRC refractory to chemotherapy and anti-EGFR mAbs. Exploratory objectives include investigating the tumor immune microenvironment within mCRC biopsies performed during the trial and correlating it with treatment activity. A manageable safety profile is observed. Although the overall efficacy endpoints are not met, biomarkers associated with clinical efficacy are identified. Patients exhibiting a high Immunoscore, strong cytotoxic and T cell proximity to tumor cells, and a high genetic immunoediting score within mCRC biopsies before treatment demonstrate significant therapeutic survival benefit, independent of RAS tumor mutation status.
    Keywords:  Immunoscore; RAS mutation; avelumab; biomarkers; cetuximab; immunoediting score; immunofluorescence; immunotherapy; metastatic colorectal cancer; transcriptomics
    DOI:  https://doi.org/10.1016/j.xcrm.2025.102201
  5. Gut. 2025 Jun 25. pii: gutjnl-2025-334851. [Epub ahead of print]
       BACKGROUND: Liver metastasis is a major cause of mortality in patients with colorectal cancer (CRC). Understanding how CRC cells influence the formation of hepatic premetastatic niches (PMNs) is crucial for developing targeted therapies.
    OBJECTIVE: We aimed to elucidate the underlying mechanism by which extracellular vesicles (EVs) derived from CRC cells with high liver metastatic capacity facilitate the formation of hepatic PMNs.
    DESIGN: CRC cells with high metastatic potential were selected using a liver metastasis mouse model through two rounds of splenic injections. The role of EVs secreted by CRC cells in the liver was investigated using lipidomics and single-cell sequencing. Clinical significance was evaluated by tumour samples from patients with CRC.
    RESULTS: EVs derived from highly metastatic CRC cells facilitate the formation of PMNs by driving hepatic lipid accumulation. The upregulation of fatty acid (FA) synthesis in CRC cells leads to significantly increased levels of prosteatogenic lipids in EVs, promoting hepatic lipid accumulation. Inhibition of hepatic lipid accumulation reduces the prometastatic capability of EVs secreted by highly metastatic CRC cells. Moreover, EVs are primarily taken up by Kupffer cells, where they induce tumour necrosis factor alpha secretion, further driving hepatic lipid accumulation. In patients with late-stage CRC, CRC cells exhibit elevated FA synthesis, which contributes to hepatic lipid accumulation. Notably, suppressing FA synthesis in CRC patient-derived organoids alleviates hepatic lipid accumulation and reduces liver metastasis.
    CONCLUSION: Inhibition of FA synthesis in CRC cells with high metastatic potential reduces hepatic lipid accumulation and subsequent metastasis, highlighting a new strategy for preventing liver metastasis.
    Keywords:  CANCER; COLORECTAL CANCER; LIPIDS
    DOI:  https://doi.org/10.1136/gutjnl-2025-334851
  6. Cell Stem Cell. 2025 Jun 18. pii: S1934-5909(25)00229-2. [Epub ahead of print]
      
    DOI:  https://doi.org/10.1016/j.stem.2025.06.007
  7. Sci Signal. 2025 Jun 24. 18(892): eadz8643
      Glycosaminoglycans enable cancer cells to take up antiferroptotic lipoproteins.
    DOI:  https://doi.org/10.1126/scisignal.adz8643
  8. Cancer Lett. 2025 Jun 17. pii: S0304-3835(25)00448-3. [Epub ahead of print] 217880
      Liver and peritoneum are the most common metastatic organs in colorectal cancer. However, the mechanisms of metastatic organotropism remain unexplored. Here we used single-cell RNA-sequencing to reveal the intermediate EMT state of tumor cells from colorectal cancer liver metastasis (CRLM) and colorectal cancer peritoneum metastasis (CRPM). There was a significant heterogeneity in expression profiles across multiple cell types in the tumor microenvironment between two groups. Although both groups of tumor cells obtained the activation of EMT, they were in different partial-EMT (pEMT) states and expressed distinct pEMT markers. Tumor cells in CRLM group were more in an epithelial-biased pEMT state, while a higher proportion of cells in CRPM group was in a mesenchymal-biased pEMT state. In addition, we observed differentially infiltrated myeloid and fibroblast sub-clusters, rendering the peritoneal metastasis group a more prominent inflammatory stimulus. Our study provides a comprehensive resource at single-cell level for in-depth exploration of metastatic organotropism in CRC.
    DOI:  https://doi.org/10.1016/j.canlet.2025.217880
  9. bioRxiv. 2025 Mar 15. pii: 2025.03.13.643008. [Epub ahead of print]
      Cancer stem cells (CSCs) are key drivers of metastasis and therapy resistance but have been challenging to visualize and study in situ . Using a fluorescent CSC reporter, we observed very different population dynamics for CSCs and nonCSCs during metastatic lung colonization in breast cancer models. CSC expansive self-renewal drives early lesion formation before switching to a maintenance mode of balanced self-renewal and differentiation, whereupon nonCSC proliferation takes over as the main driver of metastatic expansion. Mechanistic analyses showed that CSCs are hyper-responsive to microenvironmental cues such as cell crowding and nutrient availability, suggesting a novel role for CSCs as sensors and early responders to fluctuating local conditions in the tumor. Incoming signals converge on YAP/TAZ/TEAD, with heightened CSC sensitivity and response supported by elevated receptor expression and increased chromatin accessibility around enhancers with TEAD binding sites. Targeting inputs to the YAP/TAZ/TEAD node reversed chemotherapy-induced enrichment of CSCs in lung metastases.
    Highlights: Different population dynamics for breast cancer stem cells (CSCs) and their differentiated progeny in early metastatic colonizationCSCs are hyper-responsive to microenvironmental cues and serve as sensors of local conditions for the tumorMany microenvironmental inputs converge on YAP/TAZ to regulate self-renewal vs differentiation fate decisions in the CSCTargeting YAP/TAZ input pathways blocks chemotherapy-induced enrichment of CSCs.
    DOI:  https://doi.org/10.1101/2025.03.13.643008
  10. bioRxiv. 2025 Apr 24. pii: 2025.04.21.649594. [Epub ahead of print]
      Colorectal cancer (CRC) is the second leading cause of cancer deaths in the United States, with a five-year survival rate of 65%. Oxaliplatin was the first platinum drug shown to improve CRC patient outcomes and is now a common adjuvant therapy for advanced disease, yet 90% of patients develop resistance. Oxaliplatin was developed as a third-generation derivative of cisplatin, but recent evidence points to divergent modes of action. Here, genome-wide CRISPR activation and knockout screens were conducted to identify genetic changes that confer resistance to oxaliplatin in two CRC cell lines with distinct molecular backgrounds (SW620 and RKO). Guide RNAs corresponding to the neutral amino acid transporter SLC43A1 (LAT3) were the most significantly enriched in knockout screens and depleted in activation screens, suggesting a potential role for LAT3 in modulating oxaliplatin resistance. In vitro CRISPR knockout and overexpression of LAT3 in SW620 and RKO cell lines confirm increased resistance or sensitivity to oxaliplatin, respectively. Further analysis demonstrates that increased LAT3 levels corrrelate with increased intracellular levels of oxaliplatin, increased levels of DNA-platinum adducts and DNA damage, demonstrating that enhanced LAT3-mediated uptake of oxaliplatin can exert its expected mechanism of action and induce cytotoxicity. These findings may lead to a better understanding of oxaliplatin's mode of action in CRC and can provide new insights into the interplay between essential nutrient uptake and drug transport.
    STATEMENT OF SIGNIFICANCE: Oxaliplatin resistance remains a major clinical challenge for CRC treatment. Our study identified a novel role for LAT3 as a modulator of oxaliplatin sensitivity, offering new insights into drug resistance mechanisms.
    DOI:  https://doi.org/10.1101/2025.04.21.649594
  11. Science. 2025 Jun 26. eadv2367
      FOXA1 is altered in 10 to 40% of prostate cancers, yet its oncogenic mechanisms remain uncharacterized in vivo. We developed knock-in mouse models representing distinct classes of FOXA1 mutations. Histopathological and multi-omic analyses of prostate tissues and organoids revealed that Class 1 mutations, in conjunction with p53 inactivation, drive androgen-dependent adenocarcinomas through co-activation of mTORC1/2 and oncogenic AR signaling stemming from chimeric AR-half enhancers. In contrast, Class 2 mutations induce intra-luminal plasticity by reprogramming differentiated luminal cells into a progenitor-like state through activation of KLF5 and AP-1 neo-enhancer circuitries, which enables enhanced survival and proliferation even under castrate androgen levels. Our findings establish FOXA1 as a multifaceted oncogene, with distinct mutational classes divergently evolving to drive prostate tumorigenesis or therapy-resistant progression.
    DOI:  https://doi.org/10.1126/science.adv2367
  12. Nature. 2025 Jun 25.
      The nervous system has a pivotal role in cancer biology, and pathological investigations have linked intratumoural nerve density to metastasis1. However, the precise impact of cancer-associated neurons and the communication channels at the nerve-cancer interface remain poorly understood. Previous cancer denervation models in rodents and humans have highlighted robust cancer dependency on nerves, but the underlying mechanisms that drive nerve-mediated cancer aggressivity remain unknown2,3. Here we show that cancer-associated neurons enhance cancer metabolic plasticity by transferring mitochondria to cancer cells. Breast cancer denervation and nerve-cancer coculture models confirmed that neurons significantly improve tumour energetics. Neurons cocultured with cancer cells undergo metabolic reprogramming, resulting in increased mitochondrial mass and subsequent transfer of mitochondria to adjacent cancer cells. To precisely track the fate of recipient cells, we developed MitoTRACER, a reporter of cell-to-cell mitochondrial transfer that permanently labels recipient cancer cells and their progeny. Lineage tracing and fate mapping of cancer cells acquiring neuronal mitochondria in primary tumours revealed their selective enrichment at metastatic sites following dissemination. Collectively, our data highlight the enhanced metastatic capabilities of cancer cells that receive mitochondria from neurons in primary tumours, shedding new light on how the nervous system supports cancer metabolism and metastatic dissemination.
    DOI:  https://doi.org/10.1038/s41586-025-09176-8